Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
ImmunityBio, Inc. (IBRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
5Distinct source URLs
11High confidence
0.804Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ImmunityBio, Inc. Suppliers
Ticker
Name
Confidence
Evidence
JAPAN-BCG-LABORATORY
JAPAN-BCG-LABORATORY
92%
Pursuant to the Agreement, JBL will manufacture and exclusively supply Tokyo-172 strain of Bacillus Calmette-Guerin ("BCG") (the "Product") to ImmunityBio
JEFFERIES-LLC
JEFFERIES-LLC
92%
The Amendment to Sale Agreement, among other things, authorizes the issuance of an additional $459,972,480 of Shares, which were registered under the Company’s prospectus supplement dated December 23…
NANT-CAPITAL
NANT-CAPITAL
92%
On March 31, 2026, Nant Capital converted $ 25.0 million of the principal of the December 2024 Convertible Promissory Note into 4,606,596 shares of common stock
NANT-CAPITAL-LLC
NANT-CAPITAL-LLC
80%
the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer
ese other potential products. We expect to invest heavily in our other current product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to t…
Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: ese other potential products. We expect to invest heavily in our other current product candidates and in any future pr…
ImmunityBio, Inc. Customers
Ticker
Name
Confidence
Evidence
FORT-SCHUYLER-MANAGEMENT-CORPORATION
FORT-SCHUYLER-MANAGEMENT-CORPORATION
85%
g of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October 1, 2021 and as amended as of the February 14, 2…
INFINITY
INFINITY
85%
As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales dur…
OBERLAND
OBERLAND
85%
As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales dur…
ese other potential products. We expect to invest heavily in our other current product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to t…
Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: ese other potential products. We expe…
SNYNF
Sanofi
72%
or delay the development and commercialization of our product, product candidates and technologies. Our commercial success depends in part on our, our licensors’ and our collaborators’ ability to avo…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from IBRX graph: or delay the development and commercialization of our product, product candidates and technologies. Our commercial s…
IMMUNO-ONCOLOGY-CLINIC-INC
IMMUNO-ONCOLOGY-CLINIC-INC
62%
holder with the optional right to convert any portion of the outstanding principal amount into shares of the company’s common stock at any time prior to the maturity date. In accordance with ASC 470-…
NANTWORKS-LLC
NANTWORKS-LLC
62%
holder with the optional right to convert any portion of the outstanding principal amount into shares of the company’s common stock at any time prior to the maturity date. In accordance with ASC 470-…
ImmunityBio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IBRX-DEBT-10170
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
IBRX-DEBT-10169
Warrants outstanding: 3.24
90%
xbrl warrant detail from xbrl 2025-12-31.
IBRX-DEBT
Debt stack $884,000
90%
Market cache reports total debt of $884,000.
ImmunityBio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ImmunityBio, Inc..
ImmunityBio, Inc. Ownership
Holder
Name
Confidence
Evidence
IBRX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 396 tracked holders.
